1. Home
  2. MIST vs KOSS Comparison

MIST vs KOSS Comparison

Compare MIST & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • KOSS
  • Stock Information
  • Founded
  • MIST 2003
  • KOSS 1953
  • Country
  • MIST Canada
  • KOSS United States
  • Employees
  • MIST N/A
  • KOSS N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • KOSS Consumer Electronics/Appliances
  • Sector
  • MIST Health Care
  • KOSS Consumer Staples
  • Exchange
  • MIST Nasdaq
  • KOSS Nasdaq
  • Market Cap
  • MIST 81.5M
  • KOSS 63.0M
  • IPO Year
  • MIST N/A
  • KOSS N/A
  • Fundamental
  • Price
  • MIST $1.43
  • KOSS $7.34
  • Analyst Decision
  • MIST Strong Buy
  • KOSS
  • Analyst Count
  • MIST 3
  • KOSS 0
  • Target Price
  • MIST $13.00
  • KOSS N/A
  • AVG Volume (30 Days)
  • MIST 177.8K
  • KOSS 183.8K
  • Earning Date
  • MIST 11-11-2024
  • KOSS 11-08-2024
  • Dividend Yield
  • MIST N/A
  • KOSS N/A
  • EPS Growth
  • MIST N/A
  • KOSS N/A
  • EPS
  • MIST N/A
  • KOSS N/A
  • Revenue
  • MIST N/A
  • KOSS $12,265,069.00
  • Revenue This Year
  • MIST N/A
  • KOSS N/A
  • Revenue Next Year
  • MIST N/A
  • KOSS N/A
  • P/E Ratio
  • MIST N/A
  • KOSS N/A
  • Revenue Growth
  • MIST N/A
  • KOSS N/A
  • 52 Week Low
  • MIST $1.12
  • KOSS $2.27
  • 52 Week High
  • MIST $3.52
  • KOSS $18.73
  • Technical
  • Relative Strength Index (RSI)
  • MIST 42.50
  • KOSS 50.17
  • Support Level
  • MIST $1.41
  • KOSS $7.00
  • Resistance Level
  • MIST $1.53
  • KOSS $7.83
  • Average True Range (ATR)
  • MIST 0.07
  • KOSS 0.44
  • MACD
  • MIST -0.01
  • KOSS -0.01
  • Stochastic Oscillator
  • MIST 26.96
  • KOSS 32.26

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-cancelling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.

Share on Social Networks: